/ARTH
ARTH Stock - Arch Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • May 2
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.03
52W High$1.57
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $75,724 | $15,652 | $11,565 | N/A | N/A |
| Gross Profit | $-2,439 | $-35,837 | $-14,717 | $-6,926 | $-8,238 |
| Gross Margin | -3.2% | -229.0% | -127.3% | N/A | N/A |
| Operating Income | $-5,044,483 | $-5,708,806 | $-6,377,124 | $-5,370,648 | $-6,371,757 |
| Net Income | $-6,982,836 | $-4,275,854 | $-6,569,242 | $-4,012,106 | $-2,723,407 |
| Net Margin | -9221.4% | -27318.3% | -56802.8% | N/A | N/A |
| EPS | $-2.27 | $-3.56 | $-5.97 | $-4.27 | $-3.27 |
Company Overview
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ARTHBeat Rate
23%
Last 13 quarters
Avg Surprise
-98.9%
EPS vs Estimate
Beats / Misses
3/8
2 met exactly
Latest EPS
$-1.44
Q3 2024
EPS Surprise History
Q4 22
0.0%
$-2.00vs$-2.00
Q1 23
-172.0%
$-1.44vs$2.00
Q2 23
-89.5%
$0.21vs$2.00
Q3 23
-171.0%
$-1.42vs$2.00
Q4 23
-303.1%
$-0.52vs$-0.13
Q1 24
-515.4%
$-0.80vs$-0.13
Q2 24
-100.4%
$-0.33vs$74.00
Q3 24
-102.1%
$-1.44vs$70.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q2 2025 | Apr 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Dec 27, 2024 | — | — | — | — |
Q3 2024 | Aug 19, 2024 | $70.00 | $-1.44 | -102.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $74.00 | $-0.33 | -100.4% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-0.13 | $-0.80 | -515.4% | ✗ MISS |
Q4 2023 | Dec 29, 2023 | $-0.13 | $-0.52 | -303.1% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $2.00 | $-1.42 | -171.0% | ✗ MISS |
Q2 2023 | May 23, 2023 | $2.00 | $0.21 | -89.5% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $2.00 | $-1.44 | -172.0% | ✗ MISS |
Q4 2022 | Dec 28, 2022 | $-2.00 | $-2.00 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-2.00 | $-0.80 | +60.0% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-2.00 | $-0.67 | +66.6% | ✓ BEAT |
Q1 2022 | Feb 11, 2022 | $-2.00 | $-2.00 | 0.0% | = MET |
Q4 2021 | Dec 17, 2021 | — | $-1.49 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-2.00 | — | — |
Q2 2021 | May 6, 2021 | — | $-2.00 | — | — |
Q1 2021 | Feb 12, 2021 | $-4.00 | $-2.00 | +50.0% | ✓ BEAT |
Q4 2020 | Dec 11, 2020 | $-1.33 | $-1.45 | -8.8% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ARTH
What is ARTH's current stock price?
Arch Therapeutics, Inc. (ARTH) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for ARTH?
No analyst price targets are currently available for this stock.
What sector is Arch Therapeutics, Inc. in?
Arch Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ARTH's market cap?
Arch Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ARTH pay dividends?
No, Arch Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACGJ
ACI Global Corporation
$0.00
Mkt Cap: $0.0B
ALNAQ
Allena Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
BLEVF
Beleave Inc.
$0.00
Mkt Cap: $0.0B
IMVIQ
IMV Inc.
$0.00
Mkt Cap: $0.0B
MDKM
MDEChem, Inc.
$0.00
Mkt Cap: $0.0B
MICRD
Micron Solutions, Inc.
$0.00
Mkt Cap: $0.0B
MTEM
Molecular Templates, Inc.
$0.00
Mkt Cap: $0.0B
MYHI
Mountain High Acquisitions Corp.
$0.00
Mkt Cap: $0.0B
ORVRF
Orchid Ventures, Inc.
$0.00
Mkt Cap: $0.0B
WLNSF
Discover Wellness Solutions Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ARTH for comparison